Product Description
a selective TGR5 agonist, SB-756050, for patients with T2D (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27121782/)
Mechanisms of Action: TGR5 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT00733577 | P1 |
Completed |
Type 2 Diabetes |
2009-03-03 |
|
AXO110461 | P1 |
Completed |
Type 2 Diabetes |
2008-03-10 |